[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026 (Roche Press Release) - Oct 22, 2026 - "Sales growth in the Pharmaceuticals Division was +7% at CER, +2% when reported in CHF, to CHF 36.2 billion, with medicines for severe diseases continuing their strong growth. The top five growth drivers – Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo – achieved total sales of CHF 16.8 billion, an increase of +12% at CER, or +6% in CHF, compared to the first nine months of 2025."
Sales • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Chronic Spontaneous Urticaria • Colorectal Cancer • Diabetic Macular Edema • Food Hypersensitivity • Hemophilia A • HER2 Positive Breast Cancer • Immunology • Multiple Sclerosis • Wet Age-related Macular Degeneration
|